Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | STAT1 | P42224 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491049 | 1.00 | PKM (0.62) | PKMKDM4EGAALMNAALDH1A1 | |
| SCHEMBL6490508 | 0.87 | PKM (0.59) | PKMKDM4EGAALMNAALDH1A1 | |
| SCHEMBL6479618 | 0.83 | PKM (0.56) | PKMKDM4EGAALMNAALDH1A1 | |
| SCHEMBL1462317 | 0.82 | PKM (0.62) | PKMGAALMNAALDH1A1STAT1 | |
| SCHEMBL13725931 | 0.81 | NPSR1 (0.52) | PKMGAALMNAALDH1A1 | |
| SCHEMBL6478373 | 0.79 | PKM (0.51) | PKMKDM4EGAALMNAALDH1A1 | |
| SCHEMBL11628895 | 0.79 | GAA (0.86) | PKMGAALMNAALDH1A1POLB | |
| SCHEMBL587788 | 0.76 | CYP3A4 (0.68) | PKMGAALMNAALDH1A1MAOA | |
| SCHEMBL7098287 | 0.76 | MAOA (0.60) | PKMKDM4EGAALMNAALDH1A1 | |
| SCHEMBL10724066 | 0.75 | PKM (0.88) | PKMGAALMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916797-B2 | α-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2005-07-12 | — | — | US | disclosed |
| US-20030220323-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2003-11-27 | — | — | US | disclosed |
| EP-1242399-A1 | $g(a)-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS | UCB S.A. (BE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046167-A1 | α-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS | UCB, S.A. (BE) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110958-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220323-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | TACR1, TACR2, NPSR1 | PKM 928/4885KDM4E 1768/4885GAA 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.